Alvotech Financials
| ALVO Stock | USD 12.52 0.61 5.12% |
Operating Margin 0.4622 | Profit Margin (2.00) | Short Ratio 0.58 | EPS Estimate Current Year (0.41) | EPS Estimate Current Quarter (0.06) |
Alvotech |
Understanding current and past Alvotech Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Alvotech's financial statements are interrelated, with each one affecting the others. For example, an increase in Alvotech's assets may result in an increase in income on the income statement.
Alvotech Stock Summary
Alvotech competes with Fate Therapeutics, Caribou Biosciences, Arcus Biosciences, Karyopharm Therapeutics, and X4 Pharmaceuticals. Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. The company was founded in 2013 and is headquartered in Reykjavik, Iceland. Alvotech is traded on NASDAQ Exchange in the United States.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | LU2458332611 |
| CUSIP | G6715X103 L01800108 |
| Location | Luxembourg |
| Business Address | 9, Rue de |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.alvotech.com |
| Phone | 354 422 4500 |
| Currency | USD - US Dollar |
Alvotech Key Financial Ratios
| Return On Asset | -0.0761 | ||||
| Target Price | 17.4 | ||||
| Number Of Employees | 999 | ||||
| Beta | -0.097 |
Alvotech Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Alvotech's current stock value. Our valuation model uses many indicators to compare Alvotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Alvotech competition to find correlations between indicators driving Alvotech's intrinsic value. More Info.Alvotech is number one stock in return on asset category among its peers. It is rated fifth in profit margin category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Alvotech's earnings, one of the primary drivers of an investment's value.Alvotech Systematic Risk
Alvotech's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Alvotech volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Alvotech correlated with the market. If Beta is less than 0 Alvotech generally moves in the opposite direction as compared to the market. If Alvotech Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Alvotech is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Alvotech is generally in the same direction as the market. If Beta > 1 Alvotech moves generally in the same direction as, but more than the movement of the benchmark.
Alvotech Thematic Clasifications
Alvotech is part of several thematic ideas from Drugs to Health Management. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Get More Thematic IdeasAlvotech December 24, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Alvotech help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Alvotech. We use our internally-developed statistical techniques to arrive at the intrinsic value of Alvotech based on widely used predictive technical indicators. In general, we focus on analyzing Alvotech Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Alvotech's daily price indicators and compare them against related drivers.
| Downside Deviation | 1.61 | |||
| Information Ratio | 0.0913 | |||
| Maximum Drawdown | 8.63 | |||
| Value At Risk | (2.82) | |||
| Potential Upside | 3.31 |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alvotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Alvotech Stock, please use our How to Invest in Alvotech guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alvotech. If investors know Alvotech will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alvotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.70) | Earnings Share (1.85) | Revenue Per Share 1.283 | Quarterly Revenue Growth 43.997 | Return On Assets (0.08) |
The market value of Alvotech is measured differently than its book value, which is the value of Alvotech that is recorded on the company's balance sheet. Investors also form their own opinion of Alvotech's value that differs from its market value or its book value, called intrinsic value, which is Alvotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alvotech's market value can be influenced by many factors that don't directly affect Alvotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alvotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alvotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alvotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.